Gaviscon 500mg chewable tablets peppermint

País: Reino Unido

Idioma: inglés

Fuente: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredientes activos:

Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate

Disponible desde:

Reckitt Benckiser Healthcare (UK) Ltd

Código ATC:

A02BX

Designación común internacional (DCI):

Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate

Dosis:

170mg ; 500mg ; 100mg ; 25mg

formulario farmacéutico:

Chewable tablet

Vía de administración:

Oral

clase:

No Controlled Drug Status

tipo de receta:

Never Valid To Prescribe As A VMP

Resumen del producto:

BNF: 01010201

Ficha técnica

OBJECT 1
GAVISCON PEPPERMINT FLAVOUR TABLETS
Summary of Product Characteristics Updated 14-Mar-2016 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Gaviscon Peppermint Flavour Tablets.
2. Qualitative and quantitative composition
Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate
133.5 mg and calcium
carbonate 80 mg.
Excipients: Aspartame (E951) 3.75 mg per tablet.
For excipients, see Section 6.1.
3. Pharmaceutical form
Chewable tablet.
An off-white to cream, slightly mottled tablet.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid
regurgitation, heartburn and indigestion
(related to reflux), for example, following meals or during pregnancy
or in patients with symptoms related
to reflux oesophagitis.
4.2 Posology and method of administration
For oral use, after being thoroughly chewed.
Adults and children 12 years and over: Two to four tablets after meals
and at bedtime.
Elderly: No dose modifications necessary for this age group.
4.3 Contraindications
This medicinal product is contraindicated in patients with known or
suspected hypersensitivity to the
active substances or to any of the excipients.
4.4 Special warnings and precautions for use
If symptoms do not improve after seven days, the clinical situation
should be reviewed.
The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This
should be taken into account when
a highly restricted salt diet is recommended. e.g. in some cases of
congestive cardiac failure and renal
impairment.
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate.
Care needs to be taken in
treating patients with hypercalcaemia, nephrocalcinosis and recurrent
calcium containing renal calculi.
Due to its aspartame content this product should not be given to
patients with phenylketonuria.
4.5 Interaction with other medicinal products and other forms of
interaction
A time-interval of 2 hours should be considered between Gaviscon
intake and the administration